Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
Groupe d'Etudes de Lymphomes de L'Adulte HOVON - Dutch Haemato-Oncology Association German Low Grade Lymphoma Study Group OSHO Australasian Leukaemia and Lymphoma Group (ALLG) Institute of Cancer Research, United Kingdom |
---|---|
Information provided by: | Groupe d'Etudes de Lymphomes de L'Adulte |
ClinicalTrials.gov Identifier: | NCT00140582 |
Objectives
Condition | Intervention | Phase |
---|---|---|
Follicular Lymphoma |
Drug: Rituximab |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study |
Official Title: | Advanced Follicular Lymphoma Evaluating the Benefit of Maintenance Therapy With Rituximab (MabThera®) After Induction of Response With Chemotherapy Plus Rituximab in Comparison With no Maintenance Therapy |
Enrollment: | 1217 |
Study Start Date: | December 2004 |
Study medication
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Patients with at least one of the following symptoms requiring initiation of treatment:
Adequate hematological function within 28 days prior to registration (unless those abnormalities are related to lymphoma extension), this includes:
Exclusion Criteria:
Argentina | |
Fundaleu Hospital | |
Buenos Aires, Argentina, CP C1114AAN | |
Australia | |
Australian Leukemia and Lymphoma Group | |
Melbourne, Australia | |
Belgium | |
Groupe d'Etude des Lymphomes de l'adulte | |
Mont-Godinne, Belgium | |
Université de Gent | |
Gent, Belgium | |
Brazil | |
Hospital Samaritano | |
Sao Paulo, Brazil | |
Colombia | |
Fundación Santafé de Bogotá | |
Bogota, Colombia | |
Denmark | |
Amtssygehuset i Herlev | |
Herlev, Denmark | |
France | |
Centre Henri Becquerel | |
Rouen, France, 76038 | |
Centre Hospitalier Robert Debré | |
Reims, France, 51092 | |
Centre Léon Bérard | |
Lyon, France, 69008 | |
Hématologie Adultes - Hôpital Necker | |
Paris, France, 75743 | |
Hématologie CHU de Lille | |
Lille, France, 59000 | |
Hématologie CHU Purpan | |
Toulouse, France, 31059 | |
Hôpital Henri Mondor | |
Créteil, France, 94010 | |
Hôpital Saint Louis | |
Paris, France, 75010 | |
Institut Curie | |
Paris, France, 75005 | |
Institut Gustave Roussy | |
Villejuif, France | |
Polyclinique Bordeaux Nord | |
Bordeaux, France, 33300 | |
Service d'Hématologie - Centre Hospitalier Lyon-Sud | |
Pierre-Bénite cedex, France, 69495 | |
Netherlands | |
HOVON | |
Utrecht, Netherlands | |
New Zealand | |
Australia New Zealand Leukemia Lymphoma Group | |
Auckland, New Zealand | |
Peru | |
Instituo Nacional de Enfermedades Neoplasicas | |
Lima, Peru | |
Spain | |
Hospital Clinic Barcelona | |
Barcelona, Spain | |
Thailand | |
King Chulalongkorn Memorial Hospital | |
Bangkok, Thailand |
Principal Investigator: | Gilles A Salles, MD PhD | Groupe d'Etude des Lymphomes de l'Adulte |
Study ID Numbers: | PRIMA |
Study First Received: | August 22, 2005 |
Last Updated: | July 2, 2007 |
ClinicalTrials.gov Identifier: | NCT00140582 |
Health Authority: | France: Afssaps - French Health Products Safety Agency |
lymphoma follicular maintenance |
Lymphatic Diseases Immunoproliferative Disorders Rituximab Lymphoma, Follicular |
Lymphoma, Non-Hodgkin Lymphoproliferative Disorders Lymphoma Follicular lymphoma |
Neoplasms Neoplasms by Histologic Type Immunologic Factors Immune System Diseases Antineoplastic Agents |
Therapeutic Uses Physiological Effects of Drugs Antirheumatic Agents Pharmacologic Actions |